clinically developed News
-
How to Get a Promotion in Clinical Development
In today’s highly competitive CRO job market, many qualified clinical team managers (CTMs) are vying for a small number of available clinical project management (CPM) positions. You could want that promotion for more exposure, monetary benefits, or because you’re tired of being in the same spot. But how do you make yourself stand out to get that promotion? In this ...
By Brio Group
-
How to Expand your Network in the Clinical Development Industry
As a clinical development professional, you know that building and maintaining relationships is key to success. Whether you are looking to move up within your current organization or make a lateral move to another company, expanding your network can help you achieve your goals. Here are a few tips on how to expand your network in the clinical development industry. 1. Get ...
By Brio Group
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
Six Signs your Clinical Development Leadership is Failing
Efficient leadership plays a huge role in bringing a clinical trial to fruition. Pharmaceutical companies are not immune to making mistakes and facing failures. Lack of funding, safety issues, and patient dropouts are some of the struggles clinical development teams face. Some problems you as a leader may face may not always be in your control, e.g., lack of funding. Other ...
By Brio Group
-
Lung Therapeutics Announces Appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development
Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary diseases and conditions, today announced the appointment of Sharon Morriss, PhD, as Senior Vice President of Clinical Development. In this critical role, she will be responsible for guiding Lung Therapeutics’ clinical programs and will serve as a key member of the ...
-
Adiposs starts clinical development of its flagship product ImageBAT
Adiposs SA, a Geneva-based biotech company developing medical imaging products, has successfully launched its phase 1 clinical trial on August 10, with the dosing of the first human subjects with ImageBATTM, its first-in-class product for brown fat imaging. Adiposs has initiated the clinical development of its flagship imaging product, ImageBATTM. The primary objective of the IBT001 phase 1 ...
By Adiposs
-
Puzzle Medical announces partnership with MMC Medical for clinical developments
Puzzle Medical is delighted to announce our partnership with MMC Medical International Services for Puzzle Medical Devices' upcoming clinical developments. MMC is committed to its clients' clinical trials from protocol and trial design through the entire cycle of execution and study publications. Sharing nearly 30 years of industry and broad clinical experience MMC takes pride in supporting the ...
-
Investor Webinar Presentation ShareCafe Small Cap “Hidden Gems” Webinar
Vice President of Clinical Development, Dougal Thring provided an overview of the Company’s peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. To see video, please click ...
-
GI Innovation signed a contract with Medirama for joint research development of next generation innovative immuno-oncology
-GI Innovation-Medirama forms a ‘Joint Development Committee’ for professionalism maximization -Joint development for two new immuno-oncology… partial shared cooperative model of commercialization revenue GI Innovation, an innovative new drug development company signed a contract with Medirama, clinical development specialized company for joint research development of next ...
-
Nova discovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development
Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jinko®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with ...
-
FB2001 (Bofutrelvir) Phase II/III Clinical Trial Protocol Approved by NMPA
Frontier Biotech (stock code: 688221.SH) announced that the Phase II/III clinical study protocol of FB2001 (generic name: Bofutrelvir) is approved by the Center for Drug Evaluation, NMPA. The study is a worldwide multi-center, randomized, double-blind and placebo-controlled Phase II/III trial to evaluate the safety and efficacy of Bufutrelvir for hospitalized Covid-19 patients. Frontier Biotech ...
-
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma (Cambridge, MA and Paris, France) today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and ...
-
Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy
Ascelia Pharma AB (publ) (ticker: ACE) today announced the clinical development plan for Oncoral. With Oncoral, Ascelia Pharma has the opportunity to develop a novel oral chemotherapy with the potential to offer both efficacy and safety benefits to cancer patients. The planned Phase 2 study, for the treatment of gastric cancer, is expected to start in H2 2021. Further details of the Oncoral ...
-
ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). So far, two Phase I/IIa clinical trials in recurrent glioblastoma (rGBM) and metastatic, inoperable pancreatic cancer have been completed successfully. Moreover, in a follow-up ...
-
Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors. “Pam is a terrific addition to our Board,” said Mike Gaffney, Chief Executive Officer. “Her work leading the ...
-
Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC
Actym Therapeutics today announced that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors. ACTM-838 is based on the company's immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. ACTM-838 is a STACT strain that encodes ...
-
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technology Braavos Investment Advisers led the round, joined by new investor Oxford Investment ...
-
TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB®
Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed’s clinical ...
By TIKOMED AB
-
Confo Therapeutics Awarded EUR 1M VLAIO Grant For Pre-Clinical Development Of CFTX-1554, An AT2R Modulator For The Treatment Of Neuropathic Pain
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, ...
-
Polyganics Awarded €1.2 Million for Clinical Development of Liver and Pancreas Sealant Patch
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation of its Liver and Pancreas Sealant Patch. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you